Apomorphine-induced prepulse inhibition disruption is associated with a paradoxical enhancement of prepulse stimulus reactivity

被引:63
|
作者
Yee, BK [1 ]
Russig, H [1 ]
Feldon, J [1 ]
机构
[1] Swiss Fed Inst Technol, Lab Behav Neurobiol, CH-8603 Schwerzenbach, Switzerland
关键词
amphetamine; apomorphine; haloperidol; mice; prepulse inhibition; schizophrenia; startle;
D O I
10.1038/sj.npp.1300323
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Prepulse inhibition (PPI) refers to the reduction in startle reaction to a startle-eliciting stimulus when it is shortly preceded by a subthreshold prepulse stimulus. PPI has been extensively employed as an assay for sensorimotor gating, and its disruption has been characterized in specific disease conditions, including schizophrenia, In animals, dopamine agonists disrupt PPI, and this disruption can be antagonized by antipsychotic drug treatment. The present study extended these fundamental findings to C57BL6 mice, and further evaluated the subjects' reaction to the prepulse stimulus alone in relation to the expression of PPI. Not only did apomorphine (2.0 mg/kg, intraperitoneal (i.p.)) attenuate PPI but it also enhanced reactivity to the prepulse stimulus, The dual effects of apomorphine appear paradoxical in view of the positive correlation, detectable in both the control and apomorphine groups, between prepulse reactivity and PPI magnitude. The present findings contradict the hypothesis that apomorphine disrupts PPI via reduced detectability or perception of the prepulse, and we further propose that enhanced distractibility may provide a parsimonious account for the dual effects of apomorphine. Moreover, haloperidol pretreatment (0.4 mg/kg, i.p.) fully antagonized the effects of apomorphine upon prepulse reactivity as well as on PPI. The present results add to our understanding of the relevance and applicability of the PPI paradigm in modeling schizophrenia-like symptoms in animals.
引用
收藏
页码:240 / 248
页数:9
相关论文
共 50 条
  • [32] Baclofen reverses the reduction in prepulse inhibition of the acoustic startle response induced by dizocilpine, but not by apomorphine
    Bortolato, M
    Frau, R
    Aru, GN
    Orrù, M
    Gessa, GL
    PSYCHOPHARMACOLOGY, 2004, 171 (03) : 322 - 330
  • [33] Baclofen reverses the reduction in prepulse inhibition of the acoustic startle response induced by dizocilpine, but not by apomorphine
    Marco Bortolato
    Roberto Frau
    Gian Nicola Aru
    Marco Orrù
    Gian Luigi Gessa
    Psychopharmacology, 2004, 171 : 322 - 330
  • [34] Prepulse inhibition of perceived stimulus intensity: paradigm assessment
    Swerdlow, NR
    Stephany, NL
    Talledo, J
    Light, G
    Braff, DL
    Baeyens, D
    Auerbach, PP
    BIOLOGICAL PSYCHOLOGY, 2005, 69 (02) : 133 - 147
  • [35] ENHANCEMENT OF APOMORPHINE-INDUCED INHIBITION OF VOCALIZATION AFTERDISCHARGE RESPONSE BY THEOPHYLLINE
    PAALZOW, G
    PAALZOW, L
    LIFE SCIENCES, 1975, 17 (07) : 1145 - 1151
  • [36] Negative emotion-conditioned prepulse induces the attentional enhancement of prepulse inhibition in humans
    Yang, Xiaoqin
    Chen, Liangjie
    Yang, Pengcheng
    Yang, Xiaodong
    Liu, Lei
    Li, Liang
    BEHAVIOURAL BRAIN RESEARCH, 2023, 438
  • [37] The role of endogenous neurotensin in psychostimulant-induced disruption of prepulse inhibition and locomotion
    Caceda, Ricardo
    Binder, Elisabeth B.
    Kinkead, Becky
    Nemeroff, Charles B.
    SCHIZOPHRENIA RESEARCH, 2012, 136 (1-3) : 88 - 95
  • [38] Enhancement of prepulse inhibition by fear conditioning in mice
    Ishii, Daisuke
    Matsuzawa, Daisuke
    Fujita, Yuko
    Sutoh, Chihiro
    Hashimoto, Kenji
    Iyo, Masaomi
    Shimizu, Eiji
    NEUROSCIENCE RESEARCH, 2009, 65 : S111 - S111
  • [39] Stimulation in the nucleus entopeduncularis affects neuronal activity in the nucleus accumbens and medial prefrontal cortex after apomorphine-induced deficient prepulse inhibition in rats
    Schwabe, K.
    Krauss, J.
    Alam, M.
    MOVEMENT DISORDERS, 2017, 32
  • [40] Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice
    Long, LE
    Malone, DT
    Taylor, DA
    NEUROPSYCHOPHARMACOLOGY, 2006, 31 (04) : 795 - 803